Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy

被引:52
|
作者
Fisher, Jonathan [1 ]
Anderson, John [1 ]
机构
[1] UCL, London, England
来源
FRONTIERS IN IMMUNOLOGY | 2018年 / 9卷
基金
英国惠康基金;
关键词
gamma delta; chimeric antigen receptor; adoptive transfer; alpha beta T cells; cancer immunotherapy; CHIMERIC-ANTIGEN-RECEPTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; MELANOMA-ASSOCIATED ANTIGEN; GENE-THERAPY; ANTITUMOR-ACTIVITY; NK CELLS; ADOPTIVE IMMUNOTHERAPY; NONPEPTIDE ANTIGENS; HUMAN NEUROBLASTOMA; PRESENTING CELLS;
D O I
10.3389/fimmu.2018.01409
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sharing both innate and adaptive immune properties,gamma delta T cells are attractive candidates for cellular engineering. As the cancer immunotherapy field becomes increasingly busy, orthogonal approaches are required to drive advancement. Engineering of alternative effector cell types such as gamma delta T cells represents one such approach. gamma delta T cells can be modified using many of the techniques used in alpha beta T cell engineering, with the added advantage of innate-like tumor recognition and killing. Progress has been made in T-cell receptor transfer to and from gamma delta T cells as well as in a number of chimeric antigen receptor-based strategies. As the cancer immunotherapy field moves beyond repetitive iteration of established constructs to more creative solutions, gamma delta T cells may offer an attractive chassis to drive anti-tumor responses that are not only broader, but also possess a more favorable safety profile.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Advances in Engineering Cells for Cancer Immunotherapy
    Xu, Xiao
    Li, Teng
    Shen, Shiyang
    Wang, Jinqiang
    Abdou, Peter
    Gu, Zhen
    Mo, Ran
    THERANOSTICS, 2019, 9 (25): : 7889 - 7905
  • [32] gamma delta T Cell Immunotherapy-A Review
    Kobayashi, Hirohito
    Tanaka, Yoshimasa
    PHARMACEUTICALS, 2015, 8 (01): : 40 - 61
  • [33] Genome Editing in Engineered T Cells for Cancer Immunotherapy
    Bonini, Chiara
    Chapuis, Aude G.
    Hudecek, Michael
    Guedan, Sonia
    Magnani, Chiara
    Qasim, Waseem
    HUMAN GENE THERAPY, 2023, 34 (17-18) : 853 - 869
  • [34] CD19CAR T Cells From Humble Beginnings to Cancer Immunotherapy's Poster Child
    Gardner, Rebecca A.
    Jensen, Michael C.
    CANCER JOURNAL, 2014, 20 (02) : 107 - 111
  • [35] Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy
    Yuan, Megan
    Wang, Wenjun
    Hawes, Isobel
    Han, Junwen
    Yao, Zhenyu
    Bertaina, Alice
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [36] Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer
    Rahimmanesh, Ilnaz
    Khanahmad, Hossein
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2021, 16 (05) : 447 - 454
  • [37] Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy
    Simon, Bianca
    Harrer, Dennis C.
    Thirion, Christian
    Schuler-Thurner, Beatrice
    Schuler, Gerold
    Uslu, Ugur
    JOURNAL OF IMMUNOLOGICAL METHODS, 2019, 472 : 55 - 64
  • [38] RNA-electroporated T cells for cancer immunotherapy
    Pohl-Guimaraes, Fernanda
    Hoang-Minh, Lan B.
    Mitchell, Duane A.
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [39] Engineering Natural Killer Cells for Cancer Immunotherapy
    Rezvani, Katayoun
    Rouce, Rayne
    Liu, Enli
    Shpall, Elizabeth
    MOLECULAR THERAPY, 2017, 25 (08) : 1769 - 1781
  • [40] Engineering-enhanced CAR T cells for improved cancer therapy
    Milone, Michael C.
    Xu, Jie
    Chen, Sai-Juan
    Collins, McKensie A.
    Zhou, Jiafeng
    Powell, Daniel J., Jr.
    Melenhorst, J. Joseph
    NATURE CANCER, 2021, 2 (08) : 780 - 793